{"success":true,"data":{"pressRelease":{"id":"18497","rtpr_id":"nPnc16bJKa","ticker":"NKTR","exchange":"NASDAQ","all_tickers":["NKTR"],"title":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm","author":"PR Newswire","published_at":"2026-05-04T08:01:00.049Z","article_body":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm\n\nPR Newswire\n\nLOS ANGELES, May 4, 2026\n\nLOS ANGELES, May 4, 2026 /PRNewswire/ -- The Schall Law Firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2351537598&u=https%3A%2F%2Fschallfirm.com%2F&a=The+Schall+Law+Firm)\n, a national shareholder rights litigation firm, reminds investors of a class\naction lawsuit against Nektar Therapeutics (\"Nektar\" or \"the Company\")\n(NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities\nExchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.\nSecurities and Exchange Commission.\n\n(https://mma.prnewswire.com/media/2928762/SCHALL_LOGO_Logo.html)\n\nInvestors who purchased the Company's securities between February 26, 2025 and\nDecember 15, 2025, inclusive (the \"Class Period\"), are encouraged to contact\nthe firm before May 5, 2026.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2282827318&u=https%3A%2F%2Fschallfirm.com%2Fcases%2Fnektar-therapeutics-3%2F%23case-form&a=click+here+to+participate)\n.\n\nWe also encourage you to contact Brian Schall of the Schall Law Firm, 2049\nCentury Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to\ndiscuss your rights free of charge. You can also reach us through the firm's\nwebsite at www.schallfirm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2788469009&u=http%3A%2F%2Fpr.report%2FmIwBkOrU&a=www.schallfirm.com)\n, or by email at bschall@schallfirm.com (mailto:bschall@schallfirm.com) .\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nAccording to the Complaint, the Company made false and misleading statements\nto the market. Nektar's enrollment of patients for the REZOLVE-AA trial of its\nproduct candidate, rezpegaldesleukin, failed to follow protocol standards. The\ncompany's enrollment problems were likely to have a negative impact on the\ntrial's findings. The Company overstated the integrity of its REZOLVE-AA\ntrial. Based on these facts, the Company's public statements were false and\nmaterially misleading throughout the class period. When the market learned the\ntruth about Nektar, investors suffered damages.\n\nJoin the case\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=3008884202&u=https%3A%2F%2Fschallfirm.com%2Fcases%2Fnektar-therapeutics-3%2F%23case-form&a=Join+the+case)\nto recover your losses\n\nThe Schall Law Firm represents investors around the world and specializes in\nsecurities class action lawsuits and shareholder rights litigation.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of\nethics.\n\nCONTACT:\n\nThe Schall Law Firm\nBrian Schall, Esq.,\nwww.schallfirm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=1814470606&u=http%3A%2F%2Fwww.schallfirm.com%2F&a=www.schallfirm.com)\n\nOffice: 310-301-3335\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-with-the-schall-law-firm-302760946.html\n(https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-with-the-schall-law-firm-302760946.html)\n\nSOURCE The Schall Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2928762/SCHALL_LOGO_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnc16bJKa","title":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm","author":"PR Newswire","ticker":"NKTR","created":"2026-05-04T08:01:00.049Z","tickers":["NKTR"],"exchange":"NASDAQ","article_body":"NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm\n\nPR Newswire\n\nLOS ANGELES, May 4, 2026\n\nLOS ANGELES, May 4, 2026 /PRNewswire/ -- The Schall Law Firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2351537598&u=https%3A%2F%2Fschallfirm.com%2F&a=The+Schall+Law+Firm)\n, a national shareholder rights litigation firm, reminds investors of a class\naction lawsuit against Nektar Therapeutics (\"Nektar\" or \"the Company\")\n(NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities\nExchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S.\nSecurities and Exchange Commission.\n\n(https://mma.prnewswire.com/media/2928762/SCHALL_LOGO_Logo.html)\n\nInvestors who purchased the Company's securities between February 26, 2025 and\nDecember 15, 2025, inclusive (the \"Class Period\"), are encouraged to contact\nthe firm before May 5, 2026.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2282827318&u=https%3A%2F%2Fschallfirm.com%2Fcases%2Fnektar-therapeutics-3%2F%23case-form&a=click+here+to+participate)\n.\n\nWe also encourage you to contact Brian Schall of the Schall Law Firm, 2049\nCentury Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to\ndiscuss your rights free of charge. You can also reach us through the firm's\nwebsite at www.schallfirm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=2788469009&u=http%3A%2F%2Fpr.report%2FmIwBkOrU&a=www.schallfirm.com)\n, or by email at bschall@schallfirm.com (mailto:bschall@schallfirm.com) .\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nAccording to the Complaint, the Company made false and misleading statements\nto the market. Nektar's enrollment of patients for the REZOLVE-AA trial of its\nproduct candidate, rezpegaldesleukin, failed to follow protocol standards. The\ncompany's enrollment problems were likely to have a negative impact on the\ntrial's findings. The Company overstated the integrity of its REZOLVE-AA\ntrial. Based on these facts, the Company's public statements were false and\nmaterially misleading throughout the class period. When the market learned the\ntruth about Nektar, investors suffered damages.\n\nJoin the case\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=3008884202&u=https%3A%2F%2Fschallfirm.com%2Fcases%2Fnektar-therapeutics-3%2F%23case-form&a=Join+the+case)\nto recover your losses\n\nThe Schall Law Firm represents investors around the world and specializes in\nsecurities class action lawsuits and shareholder rights litigation.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of\nethics.\n\nCONTACT:\n\nThe Schall Law Firm\nBrian Schall, Esq.,\nwww.schallfirm.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679419-1&h=1814470606&u=http%3A%2F%2Fwww.schallfirm.com%2F&a=www.schallfirm.com)\n\nOffice: 310-301-3335\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-with-the-schall-law-firm-302760946.html\n(https://www.prnewswire.com/news-releases/nktr-investors-have-opportunity-to-lead-nektar-therapeutics-securities-fraud-lawsuit-with-the-schall-law-firm-302760946.html)\n\nSOURCE The Schall Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2928762/SCHALL_LOGO_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T08:01:00.082338068Z","server_sent_at_ms":1777881660082},"received_at":"2026-05-04T08:01:00.141Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}